Rifaximin-extended intestinal release induces remission in patients with moderately active crohn's disease

Cosimo Prantera, Herbert Lochs, Maria Grimaldi, Silvio Danese, Maria Lia Scribano, Paolo Gionchetti

Research output: Contribution to journalArticlepeer-review

Abstract

Background & Aims: Bacteria might be involved in the development and persistence of inflammation in patients with Crohn's disease (CD), and antibiotics could be used in therapy. We performed a clinical phase 2 trial to determine whether a gastroresistant formulation of rifaximin (extended intestinal release [EIR]) induced remission in patients with moderately active CD. Methods: We performed a multicenter, randomized, double-blind trial of the efficacy and safety of 400, 800, and 1200 mg rifaximin-EIR, given twice daily to 402 patients with moderately active CD for 12 weeks. Data from patients given rifaximin-EIR were compared with those from individuals given placebo, and collected during a 12-week follow-up period. The primary end point was remission (Crohn's Disease Activity Index

Original languageEnglish
Pages (from-to)473-481
Number of pages9
JournalGastroenterology
Volume142
Issue number3
DOIs
Publication statusPublished - Mar 2012

Keywords

  • IBD
  • Inflammation
  • Intestinal Microbiota
  • Nonabsorbed Antibiotic

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Rifaximin-extended intestinal release induces remission in patients with moderately active crohn's disease'. Together they form a unique fingerprint.

Cite this